FDA wants more data on an extended-release form of J&J's Nucynta

10/4/2010 | MSNBC

Johnson & Johnson has received a complete-response letter from the FDA for an extended-release version of pain drug Nucynta. The agency asked for additional information about the treatment's conversion to a formulation designed to be break- and crush-resistant.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care